|
| |
ITA Partners reviews information with patients, listens and addresses knowledge gaps, facilitates follow-through on next steps and compliance with treatment regimens, and helps patients prepare for upcoming doctors’ visits.
|
| |
OncoIQSM, our proprietary electronic system, helps us ensure that treatment meets evidence-based, national cancer guidelines. In a supportive role to physicians, ITA has ongoing conversations with patients to reinforce their care and electronically tracks their progress. ITA’s role with insurers includes verifying the appropriateness of treatment. Importantly, the nationally renowned members of ITA’s Medical Advisory Board lend unparalleled guidance to our full spectrum of services. |
| |
ITA Partners saves patients, families and insurers thousands of dollars by reviewing treatment plans, monitoring costs, and improving patient compliance in order to reduce complications. Our education and counseling helps patients to make good decisions, minimize side effects during treatment, and often, return to normal life in timely fashion. If cancer does progress, ITA is an added source of support, helping patients, families and physicians deal with life’s toughest decisions. |
|
Costly Issues ITA Partners Helps Avoid
The following provides a glimpse of our role…
Most chemotherapy treatment is performed "off-label," meaning its federally approved use does not match the patient’s exact clinical situation. Such "off-label" use in cancer usually is medically appropriate and guided by medical evidence. ITA’s expert staff and proprietary technology assess and validate treatment plans to ensure they conform with evidence-based guidelines and insurance policy language. This helps insurers know they’re paying for the right treatment, saves physicians hours of work documenting medical necessity, and helps patients secure timely approval of best-possible care.
New therapies that target abnormalities in specific types of cancer cells are emerging rapidly, improving clinical outcomes for patients with those cancer types or tumors with the given abnormalities. ITA reviews the patient’s clinical status to assure these therapies are used in cases where they can have positive medical benefit.
New technologies such as positron emission tomography (PET scan) and image-guided or stereotactic radiation therapies have the potential to enhance diagnostic and treatment capabilities. However, many tumor types and clinical situations do not require these technologies, which are increasingly available and prescribed. ITA reviews clinical situations to affirm use of these high-cost services provides true value to patients and insurers. |
|
